Aytu BioPharma, Inc. (AYTU)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
AYTU Insider Trading Activity
AYTU Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $19,500 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Disbrow Joshua R. | Chief Executive Officer | 1 | $19,500 | 0 | $0 | $19,500 |
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Insider Activity of Aytu BioPharma, Inc.
Over the last 12 months, insiders at Aytu BioPharma, Inc. have bought $19,500 and sold $0 worth of Aytu BioPharma, Inc. stock.
On average, over the past 5 years, insiders at Aytu BioPharma, Inc. have bought $2.05M and sold $9.44M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Disbrow Joshua R. (Chief Executive Officer) — $19,500.
The last purchase of 15,000 shares for transaction amount of $19,500 was made by Disbrow Joshua R. (Chief Executive Officer) on 2025‑02‑28.
List of Insider Buy and Sell Transactions, Aytu BioPharma, Inc.
| 2025-02-28 | Disbrow Joshua R. | Chief Executive Officer | 15,000 0.245% | $1.30 | $19,500 | -2.71% | ||
| 2023-06-16 | PYSZCZYMUKA GREG | Chief Commerical Officer | 12,000 0.3307% | $1.87 | $22,428 | +53.30% | ||
| 2023-06-14 | Disbrow Joshua R. | Chief Executive Officer | 14,000 0.3999% | $1.86 | $26,079 | +59.14% | ||
| 2022-12-19 | Disbrow Joshua R. | Chief Executive Officer | 112,371 0.1842% | $0.22 | $25,048 | -47.73% | ||
| 2022-12-19 | PYSZCZYMUKA GREG | Chief Commercial Officer | 100,000 0.18% | $0.24 | $24,480 | -47.73% | ||
| 2022-11-18 | Disbrow Joshua R. | Chief Executive Officer | 222,000 0.3705% | $0.24 | $52,614 | -50.00% | ||
| 2022-11-18 | Oki Mark K | Chief Financial Officer | 90,000 0.1458% | $0.23 | $20,700 | -50.00% | ||
| 2020-12-11 | ARMISTICE CAPITAL, LLC | director | 1.33M 9.5911% | $6.00 | $8M | -17.04% | ||
| 2020-04-27 | Sale | ARMISTICE CAPITAL, LLC | director | 5.11M 4.0608% | $1.82 | $9.3M | -49.75% | |
| 2020-04-15 | Sale | Cerecor Inc. | 10 percent owner | 92,777 0.082% | $1.55 | $144,092 | -33.23% | |
| 2020-03-10 | Sale | ARMISTICE CAPITAL, LLC | director | 22.03M 43.1464% | $1.42 | $31.2M | -41.46% | |
| 2019-12-20 | ARMISTICE CAPITAL, LLC | 26,000 0.1525% | $0.88 | $22,880 | +39.53% | |||
| 2019-12-19 | ARMISTICE CAPITAL, LLC | 52,788 0.3082% | $0.85 | $44,870 | +44.58% | |||
| 2019-12-19 | Disbrow Joshua R. | 55,000 0.3354% | $0.89 | $48,824 | +44.58% | |||
| 2018-12-21 | Sale | Green David A | Chief Financial Officer | 3,330 0.053% | $0.81 | $2,711 | +74.68% | |
| 2018-03-06 | Disbrow Joshua R. | Chief Executive Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | ||
| 2018-03-06 | Disbrow Jarrett | Chief Operating Officer | 226,105 2.044% | $0.45 | $101,747 | -49.76% | ||
| 2018-03-06 | Green David A | Chief Financial Officer | 66,600 0.6021% | $0.45 | $29,970 | -49.76% | ||
| 2016-11-02 | Disbrow Joshua R. | Chief Executive Officer | 333,332 4.4318% | $1.68 | $559,998 | -70.09% | ||
| 2016-11-02 | Disbrow Jarrett | Chief Operating Officer | 333,332 4.4318% | $1.68 | $559,998 | -70.09% |
Insider Historical Profitability
| Disbrow Joshua R. | Chief Executive Officer | 86591 1.4035% | $104,333.50 | 9 | 0 | <0.0001% |
| Cerecor Inc. | 10 percent owner | 9713068 157.4279% | $11.7M | 0 | 1 | |
| DOCKERY CARL | director | 5047591 81.8106% | $6.08M | 1 | 0 | |
| ARMISTICE CAPITAL, LLC | director | 1333334 21.6105% | $1.61M | 3 | 2 | <0.0001% |
| Disbrow Jarrett | Chief Operating Officer | 439490 7.1232% | $529,541.50 | 4 | 0 | |
| Gould Gregory A | Chief Financial Officer | 273565 4.4339% | $329,618.47 | 1 | 0 | |
| Green David A | Chief Financial Officer | 266250 4.3153% | $320,804.63 | 1 | 1 | |
| Oki Mark K | Chief Financial Officer | 190000 3.0795% | $228,931.00 | 1 | 0 | <0.0001% |
| Cantrell Gary | director | 98333 1.5938% | $118,481.43 | 1 | 0 | |
| PYSZCZYMUKA GREG | Chief Commerical Officer | 21935 0.3555% | $26,429.48 | 2 | 0 | +2.78% |
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $76.27M | |
$22,899,264 | 81 | 34.90% | $26.7M | |
$125,860,243 | 57 | -4.48% | $54.94M | |
$2,740,482 | 50 | 9.37% | $36.33M | |
$30,209,812 | 45 | -1.91% | $8.36M | |
$6,453,272 | 41 | -4.22% | $20.14M | |
$3,140,759 | 30 | 10.79% | $11.73M | |
$6,021,989 | 30 | -0.17% | $280.79M | |
$423,174,478 | 29 | -7.58% | $39.9M | |
$1,507,654 | 22 | -23.16% | $53.9M | |
$25,034,841 | 20 | 9.38% | $238.44M | |
$32,330,336 | 13 | -9.80% | $16.85M | |
$934,616 | 12 | 74.76% | $1.69M | |
$4,039,981 | 8 | -49.09% | $11.26M | |
Aytu BioPharma, Inc. (AYTU) | $8,171,353 | 7 | -14.29% | $7.43M |
$520,771 | 5 | 60.82% | $109.67M | |
$103,523 | 3 | 9.40% | $69.18M | |
$12,000 | 2 | -97.93% | $5.23M | |
$5,003,136 | 1 | -14.58% | $239.55M |
AYTU Institutional Investors: Active Positions
| Increased Positions | 12 | +46.15% | 39,926 | +1.95% |
| Decreased Positions | 7 | -26.92% | 207,484 | -10.13% |
| New Positions | 7 | New | 36,785 | New |
| Sold Out Positions | 2 | Sold Out | 14,562 | Sold Out |
| Total Postitions | 31 | +19.23% | 2M | -8.18% |
AYTU Ownership Change vs Market
Institutional Investor Ownership
| Nantahala Capital Management, Llc | $1,402.00 | 18.11% | 1.09M | 0 | 0% | 2024-12-31 |
| Stonepine Capital Management, Llc | $526.00 | 6.79% | 407,549 | -93,409 | -18.65% | 2024-12-31 |
| Armistice Capital, Llc | $194.00 | 2.5% | 150,000 | -86,000 | -36.44% | 2024-12-31 |
| Renaissance Technologies Llc | $97.00 | 1.26% | 75,423 | +700 | +0.94% | 2024-12-31 |
| Geode Capital Management, Llc | $55.00 | 0.71% | 42,733 | -2,369 | -5.25% | 2024-12-31 |
| Vanguard Group Inc | $36.00 | 0.47% | 27,888 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $29.00 | 0.38% | 22,793 | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $19.00 | 0.24% | 14,622 | 0 | 0% | 2024-12-31 |
| Two Sigma Securities, Llc | $15.00 | 0.2% | 11,690 | +11,690 | New | 2024-12-31 |
| Citadel Advisors Llc | $14.00 | 0.18% | 11,062 | +11,062 | New | 2024-12-31 |